Battling Neuropathic Scar Pain With Botulinum Toxin
September 2019 | Volume 18 | Issue 9 | Case Reports | 937 | Copyright © September 2019
Andrew Schuler BS,ª Jesse Veenstra MD PhD,B David Ozog MDb
aUniversity of Michigan Medical School, Ann Arbor, MI
BDepartment of Dermatology, Henry Ford Health System, Detroit, MI
Botulinum toxin type A (BTA) is a neurotoxic protein that prevents the release of neurotransmitters from presynaptic nerves and has shown promise in treating neuropathic pain. Recently, BTA has been used to treat painful keloids and scars. We present a patient with refractory neuropathic pain in a normotrophic spread-scar treated with the injection of BTA.
A 47-year-old Caucasian female with a history of invasive melanoma of the left upper arm presented with pain in her excision scar, which she described as a “pins and needles” sensation alternating with a dull, deep ache. She had previously tried topical lidocaine, topical and intralesional steroids, and oral gabapentin without improvement. We treated the patient with 50 U of onabotulinumtoxinA intradermally at 1-1.5 cm intervals within and immediately around the perimeter of the scar. At 1-week follow-up, she reported a 10% decrease in her pain. Four weeks after the procedure, she reported a 50% decrease in pain with smoothening of the scar surface, which has been durable for over 5 months. Scar pain can significantly impair quality of life and treatment protocols have not been established for normotrophic scars. Many trials have focused on improving appearance and reducing symptoms in hypertrophic and keloid scars, but few have evaluated therapies for normotrophic scars. BTA has been studied as a treatment for painful hypertrophic and keloid scars with promising results. Our patient had a marked reduction in pain and improvement in scar texture at 1-month follow-up, which has been maintained thus far, indicating that intradermal BTA may be a simple and useful tool in treating painful normotrophic scars.
J Drugs Dermatol. 2019;18(9):937-938.
Botulinum toxin type A (BTA) is a neurotoxic protein that binds to soluble N-ethylmaleimide-sensitive factor attachment protein receptor, preventing release of neurotransmitters from presynaptic nerves.1 BTA is hypothesized to directly exert analgesic properties by reducing release of mediators like substance P, glutamate, and calcitonin gene related peptide (CGRP); in one mouse model of neuropathic pain, a single injection of BTA was shown to significantly reduce allodynia for up to 3 weeks.1,2 Clinically, BTA has shown promise in treating disorders characterized by neuropathic pain, including trigeminal neuralgia, postherpetic neuralgia, diabetic neuropathy, as well as postsurgical neuropathic pain from thoracotomies, carpal tunnel surgery and more.1,3-5 Recently, there have also been successful reports using BTA to treat painful keloid scars and postoperative Mohs scars.6-8 Here, we present a patient with refractory neuropathic pain in a normotrophic spread-scar successfully treated with injection of BTA.
the left upper arm presented with pain at the site of her excision scar. Her melanoma was removed by wide local excision 5 years prior; after the incision healed she began to experience constant pain in the scar. She described the pain as a “pins and needles” sensation that alternated with a dull, deep ache. The pain significantly impacted her quality of life, waking her from sleep and preventing her from lying on her left side. She also noticed surface changes of the skin that left the scar uneven to the touch. She had previously tried topical lidocaine and topical and intralesional steroids without any effect. She had used gabapentin 100 mg three times daily but stopped taking it due to sedation. On physical examination there was a 15-cm normotrophic, slightly pink surgical scar with prominent spreading of the inferior two-thirds of the scar on the left upper lateral arm (Figure 1A).
To treat the scar, 50 units of BTA were injected intradermally at 1-1.5 cm intervals within and immediately around the perimeter of the scar (Figure 1B). The patient tolerated the procedure well with minimal pain and no complications. At a 1-week follow-up, there was a self-reported 10% decrease in pain associated with the scar. Four weeks after the procedure, the patient reported a 50% decrease in her pain from baseline along with relaxation and smoothening of the scar surface. These effects have been sustained greater than 5 months after treatment.